Gyre Therapeutics Inc. (GYRE)
GYRE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1124105/000119312526106251/0001193125-26-106251-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GYRE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2006 |
| SEC CIK | 0001124105 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $116.6M |
| Net income | $9.9M |
| Operating income | $11.5M |
| Net margin | 8.5% |
| Operating margin | 9.9% |
| Revenue growth | +10.2% |
| Cash | $37.1M |
| Total assets | $166.1M |
| P/E (computed) | 51.2× |
| P/S (computed) | 4.3× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-06 |
| Cash and burn | $41.6M cash; operating cash flow -$1.6M a quarter. | Report 2026-09-30 |
| Shares outstanding | 115,321,017 (2026-11-01); 96,333,157 a year earlier; 37,978,142 three years earlier. 3y figure adjusted for splits (1-for-15 overall). | Cover page 2026-11-01 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 1 S-3/F-3 shelf filings; 0 424B5 takedowns | Latest 2026-06-23 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Grant Thornton Zhitong Certified Public Accountants LLP, Beijing, China | PCAOB Form AP 2026-03-20 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $953K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $32.9M | -$2.5M | -$4.0M | $41.6M | No debt tags | $108.1M | 10-Q 2026-11-06 |
| Q2 2026 2026-06-30 | $29.1M | -$14.3M | -$16.7M | $43.3M | No debt tags | $107.9M | 10-Q 2026-08-07 |
| Q1 2026 2026-03-31 | $22.5M | -$18.6M | $3.2M | $37.5M | No debt tags | $108.5M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | $23.6M | -$1.3M | $11.2M | $49.2M | No debt tags | $108.1M | 10-K 2026-03-13 |
| Q3 2025 2025-09-30 | $32.7M | $1.9M | -$2.6M | $40.4M | No debt tags | $112.4M | 10-Q 2026-11-06 |
| Q2 2025 2025-06-30 | $29.7M | -$2.2M | -$7.5M | $36.5M | No debt tags | $105.2M | 10-Q 2026-08-07 |
| Q1 2025 2025-03-31 | $22.1M | $4.9M | -$129K | $15.0M | No debt tags | $100.6M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $27.9M | $598K | -$2.8M | $11.8M | No debt tags | $105.8M | 10-K 2026-03-13 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | S-3 | 2026-06-23 |
| Latest annual report | 10-K | 2026-03-13 |
| Latest quarterly / interim | 10-Q | 2026-11-06 |
| Latest current report | 8-K | 2026-11-05 |
| Latest proxy | DEFA14A | 2026-05-04 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -9.5% |
| 1 month | -35.8% |
| 3 months | -34.1% |
| Year to date | -39.0% |
| 1 year | -46.7% |
| From 52-week high | -50.8% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CBIO | Crescent Biopharma Inc. | $13.50 | -4.59% | $525.1M |
| MNPR | Monopar Therapeutics Inc. | $71.97 | -0.04% | $487.7M |
| INDP | Indaptus Therapeutics Inc. | $3.45 | +8.83% | $529.9M |
| CAPR | Capricor Therapeutics Inc. | $8.30 | -12.91% | $482.6M |
| NGNE | Neurogene Inc. Common Stock | $23.30 | -2.63% | $482.3M |
| PHAT | Phathom Pharmaceuticals Inc. | $5.88 | -2.97% | $478.0M |
| STTK | Shattuck Labs Inc. | $4.66 | +0.21% | $474.6M |
| AQST | Aquestive Therapeutics Inc. | $3.76 | -3.84% | $472.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier